Effects of Xalatan� (latanoprost) or Travatan (travoprost) on by 0QJ2MuW1

VIEWS: 51 PAGES: 11

									  Effects of Xalatan® (latanoprost) or
   Travatan® (travoprost) on Ocular
Surface Signs and Symptoms in Ocular
 Hypertensive or Glaucoma Patients.
     M.B. McDonald1, R.T. Sturm6, R.M. Caronia6, P.R. Galstian6, G. D'Aversa3, R.G.
       Fumuso2, E.D. Donnenfeld1, H.D. Perry2, J.R. Wittpenn, Jr.5, J.K. Oats5, M.A.
                          Swerdin3, D.M. Sachs4, R.E. Mariani6.
    1Ophthalmology, Ophthalmic Consultants of Long Island, Lynbrook and Rockville Centre,   NY;
            2Ophthalmology, Ophthalmic Consultants of Long Island, Rockville Centre, NY;
             3Ophthalmology, Ophthalmic Consultants of Long Island, Valley Stream, NY;
             4Ophthalmology, Ophthalmic Consultants of Long Island, East Meadow, NY;
              5Ophthalmology, Ophthalmic Consultants of Long Island, Stony Brook, NY;
                6Ophthalmology, Ophthalmic Consultants of Long Island, Lynbrook, NY




  The authors of this poster have received research funding from Pfizer Inc.
                              Revised Abstract
Purpose: Burning and stinging associated prostaglandin instillation are associated with treatment failures due to non-
compliance, it is worse in patients with dry eye. This pilot study examines potential differences in the ocular signs and
symptoms in patients treated with either latanoprost or travoprost, based subjective and clinical assessments.

Methods: The study includes up to 40 patients (80 eyes) with ocular hypertension or glaucoma with mild to moderate dry
eye (≤Grade 3, Oxford Grading Scale) enrolled to complete four visits over two months. Initially, screened patients are
allowed 4-28 days to washout of their current medication after which patients are randomized to receive either drug
(baseline). Patients follow treatment regimen until exit at day 56. Primary endpoint is the OSDI scores (patient’s subjective
assessment) while secondary endpoints are clinical: TBUT, corneal assessment, lissamine green staining, and slit-lamp exam.
All evaluations are performed by a masked investigator. ANOVA was performed to compare treatment outcomes.

Results: At day 56, both treatments did not have a significant impact on OSDI when compared to baseline (p=0.7 for
travoprost and p=0.9 for latanoprost, n=5/group). TBUT remained unchanged for latanoprost (p=0.9, n=5), but was
significantly lower than baseline after travoprost treatment (p=0.04, n=5). Tear flow remained statistically unchanged after
travoprost (p=0.2, n=5) or latanoprost (p=0.5, n=5) treatment. BCVA after travoprost and latanoprost treatment was not
affected (p=0.9 for travoprost and p=0.7 for latanoprost, n=5/ group). Central corneal grading (p=0.2, n=5), lissamine
staining (p=0.6, n=5) and slit lamp biomicroscopy (p=0.4, n=5) scores remained unchanged when compared to baseline. In
an ongoing study, Travatan Z® (travoprost) is also compared to latanoprost. Preliminary results indicate no significant
differences in OSDI scores between treatment groups (p>0.2, n=4).

Conclusions: In this interim report. travoprost or latanoprost treatments did not statistically change patients subjective
assessment. The only statistically significant finding was after travoprost treatment, TBUT decreased (worsened) over the
treatment period (p=0.04, n=5). Studies are currently ongoing to compare Travatan Z® (travoprost) to latanoprost.
                     Introduction

•   Prostaglandins are a popular choice for treatment of ocular
    hypertension or glaucoma because of their clinical efficacy
    and once-daily dosing schedule.

•   Unfortunately the burning and stinging associated with
    their instillation contributes to treatment failures due to
    non-compliance, which is worse in patients with dry eye.

•   This pilot study examines potential differences in the
    ocular signs and symptoms in patients treated with either
    latanoprost or travoprost, based subjective and clinical
    assessments.
                            Methods
•   This initial study was performed with 5 patients in each treatment group
    and is set to enroll 40 patients (80 eyes).
•   Patients with ocular hypertension or glaucoma with mild to moderate dry
    eye (≤Grade 3, Oxford Grading Scale) were enrolled to complete four
    visits over two months.
•   At the 1st visit, screened patients are allowed 4-28 days to washout of
    their current medication.
•   The 2nd visit is the baseline where patients are randomized to receive
    either Xalatan® (latanoprost ophthalmic solution) or Travatan® (travoprost
    ophthalmic solution) .
•   Patients follow treatment regimen until exit at day 56.
•   Primary endpoint is the OSDI scores (patient’s subjective assessment).
•   Secondary endpoints are clinical: TBUT, corneal assessment, lissamine
    green staining, and slit-lamp exam.
•   All evaluations are performed by a masked investigator.
•   ANOVA was performed to compare treatment outcomes.
                                     Results
                                 OSDI Scores                         Worse
      25


      20


      15


      10                                                 Travatan®
                                                         Xalatan ®
       5


       0


       -5
            Baseline   Visit 2       Visit 3   Visit 4
                                                                     Better


•   Both treatments had no statistically significant impact on OSDI scores.
•   There were no significant differences in OSDI scores over the treatment
    period compared to baseline (p=0.7 for Travatan® and p=0.9 for Xalatan®,
    n=5 per group).
•   The lower the OSDI score the lower the dry eye related disease severity.
                                            Results
                                  Tear Breakup Time                               Better
                  10

                   9

                   8

                   7

                   6
     Time (sec)




                   5                                                  Travatan®

                   4                                                  Xalatan ®

                   3

                   2

                   1
                                                           *
                                                      (P=0.04, n=5)

                   0
                       Baseline   Visit 2   Visit 3       Visit 4                 Worse


•   TBUT remained unchanged for Xalatan® (p=0.9, n=5).

•   * On visit 4, TBUT was significantly lower than baseline after
    Travatan® treatment (p=0.04, n=5).
                                   Results
                               Shirmer Test                          Better
         25



         20



         15
    mm




                                                         Travatan®

         10                                              Xalatan ®



          5



          0
              Baseline   Visit 2     Visit 3   Visit 4
                                                                     Worse

•   Tear flow remained statistically unchanged after Travatan®
    (p=0.2, n=5) or Xalatan® (p=0.5, n=5) treatment over the
    treatment period.
                                   Results
                      Best Corrected Visual Acuity                  Vision Loss
                               (log MAR)


     0.7



                                                        Travatan®
                                                        Xalatan ®
     0.2




    -0.3                                                            Better Visual
           Baseline      Visit 2    Visit 3   Visit 4
                                                                       Acuity

•   BCVA was measured using the logMAR (minimum angle of
    resolution).
•   BCVA after Travatan® and Xalatan® treatment was not affected
    (p=0.9 for Travatan® and p=0.7 for Xalatan®, n=5 per group).
                             Results
      Secondary Evaluation Criteria

•   After visit 4 (56 days after treatment with either Travatan® or
    Xalatan®), secondary evaluation criteria such as central corneal
    grading (p=0.2, n=5), lissamine staining (p=0.6, n=5) and slit lamp
    biomicroscopy (p=0.4, n=5) scores remained unchanged when
    compared to baseline.
                                       Results
                              OSDI Scores                           Worse
    25


    20


    15

                                                      Travatan Z®
    10
                                                      Xalatan ®
                                                      Travatan ®
     5


     0


    -5
         Baseline   Visit 2       Visit 3   Visit 4                 Better

•   In an ongoing study, Travatan Z® is also compared to Xalatan®.
•   Preliminary OSDI scores measured at final patient visit (visit 4) indicate
    no statistically significant differences between treatment groups
    (p>0.2, n=4).
•   The lower the OSDI score the lower the dry eye related disease
    severity.
                    Conclusions
•   In this interim report, Travatan® and Xalatan®
    treatments, did not statistically change the patients
    subjective assessment.

•   The only statistically significant finding was in the
    Travatan® treatment group, where TBUT decreased
    (worsened) over the treatment period (p=0.04, n=5).

•   Studies are currently ongoing to compare Travatan Z®
    to Xalatan®.

								
To top